Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spanish study looks back at targeted cancer Drug's Real-World impact

NCT ID NCT06837090

Knowledge-focused Sponsor: Grupo Espanol de Tumores Neuroendocrinos Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at the medical records of 19 Spanish patients with rare NTRK fusion cancers who received the targeted drug larotrectinib before it was widely available. The goal was to see how well the drug worked in real-world settings. The study did not involve new treatments or visits, just data collection from past care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cancer patients with solid neoplasms with NTRK fusions.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Infant and adult patients (all ages). 2. Patients with confirmed diagnosis of solid neoplasms. 3. Patients must have detected NTRK fusions by the following diagnostic methods NGS, fluorescence in situ hybridization (FISH) and/or Immunohistochemistry (IHC). 4. Patients must be treated with Larotrectinib under the compassionate use program (before the commercialization) in order to be included in the study. 5. Data should be available in order to evaluate effectiveness and consequent follow up. Exclusion Criteria: 1. Patients with solid neoplasms treated with Larotrectinib in clinical trials or other settings different from clinical practice. 2. Patients that initiated treatment with Larotrectinib after the obtention of prize-reimbursement and commercialization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid neoplasms with NTRK fusions are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm NTRK fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid neoplasms with NTRK fusions

Contacts and locations

Locations

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Clínico Santiago de Compostela

    Santiago de Compostela, La Coruña, 15706, Spain

  • Hospital Quirón Salud Torrevieja

    Torrevieja, Alicante, 03184, Spain

  • Hospital San Joan de Deu

    Esplugues de Llobregat, Barcelona, 08950, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Infanta Sofía

    San Sebastián de los Reyes, Madrid, 28702, Spain

  • Hospital Universitario Insular de Gran Canaria

    Las Palmas de Gran Canaria, Las Palmas, 35016, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, 27003, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Son Espases

    Palma, Baleres, 07120, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario de Cruces

    Barakaldo, Bizkaia, 48903, Spain

  • Hospital Universitario de Navarra

    Pamplona, Navarre, 31008, Spain